Promoting the Quality of Medicines (PQM) Program Technical Assistance

Paul Nkansah, MSc., MEng., Ph.D.
Deputy Director – Technical
Promoting the Quality of Medicines Program
U.S. Pharmacopeial Convention

Workshop for NMRAs and Manufacturers of Medicines for Treatment of Tuberculosis and Neglected Tropical Diseases

Bangkok, Thailand
July 25-27, 2017
Overview of the USP PQM Program

Overview of USP PQM technical assistance to manufacturers and national regulatory agencies

USP PQM contributions to improving standards of practice in LMICs and the resulting public health impact

Conclusion
PQM is the result of a cooperative agreement between US Agency for International Development (USAID) and United States Pharmacopeia.

In fulfillment of USP and USAID missions, PQM serves as a mechanism to help USAID-supported countries strengthen their quality assurance systems to better ensure the quality, safety and efficacy of medical products that reach patients.

This collaboration between USP and USAID is a 25-year long partnership!
**Goal:** Strengthen quality assurance systems to sustainably ensure the quality and safety of medical products, and thereby protect public health

**IR1: Medical products quality assurance systems strengthened**
- **IR 1.1** Quality assurance policies, legislation, guidelines and procedures improved
- **IR 1.2** Registration, inspection and licensing functions of medicine regulatory agencies sustainably improved (Pre-market)
- **IR 1.3** Standard of practices at national quality control laboratories sustainably improved
- **IR 1.4** Institutional capacity for regulatory workforce sustainably improved
- **IR 1.5** Capacity for post-marketing surveillance of medical products sustainably improved

**IR2: Supply of quality assured priority medicines increased**
- **IR 2.1** Quality assured priority medicines produced locally increased
- **IR 2.2** Quality assured priority medicines produced globally increased
- **IR 2.3** CROs compliance with Good Clinical practices and Good Laboratory practices increased
- **IR 2.4** Sources of quality assured API and FPP diversified and supply secured

**IR3: Utilization of medical product quality information for decision-making increased**
- **IR 3.1** Availability of information related to quality of medical products increased
- **IR 3.2** Enforcement actions against falsified, substandard and unapproved medical products increased
- **IR 3.3** Information on quality assurance of medical products used for advocacy increased
Regulatory System Quality Assurance

**ADMINISTRATIVE ELEMENTS**
- Policy, legislation, regulations
- Human Resources
- Finance
- Infrastructure

New Legislation/Regulations; Revise/reform existing regulations, policies as requested
Establish/Strengthen regulatory workforce (define structure, competencies)

**TECHNICAL ELEMENTS**
- Standards
- Specifications
- Guidelines
- Procedures

**REGULATORY FUNCTIONS**
- Licensing of premises, practices & persons
- Inspection of manufacturers & distributors
- Product assessment & registration
- Quality control of labs & QC of products
- BE / Clinical Practice (GCPs)
- PMS (Quality) & PMS (Safety)

**IRIMS – Content / Guidelines / Standards**

Source: Modified from Ratanawijtrasi/Wondemagegnehu 2002, 12.

- Support GMP Licensing of manufacturers, distributors, warehouse and other pharmaceutical premises
- Build Capacity of inspectorates GMPs, GLPs, GDPs, GSP, and GCPs Inspections
- Training in Good dossier review practices (GDRev)
- Training in QMS, GLPs, Testing, etc. toward WHO PQ ISO 17025
- Training in GCP Reqs. & Inspections
- Help develop PMS program (Guidelines and protocol)
- Help train on PMS

**Red boxes:** Primary areas of primary PQM mandate
Training by regulatory technical area 2009 - Present

(7225 Individuals - 51% female)

30 National Regulatory Agency
(Africa, MENA, Asia, LAC, CIS)
Laboratory Services
Laboratory Quality Management Services

- Works collaboratively with NQCLs to build/strengthen Quality Management Systems to international standards of practice
  - Systems for facility, equipment, management, personnel
  - Guidelines, procedures and processes
  - Good Laboratory and Documentation Practices
  - Proficiency in quality control testing
  - Internal audit
  - Corrective and Preventive Actions

- Supports NQCLs to comply with international standard for laboratories, leading to ISO/IEC 17025 accreditation and/or WHO Prequalification
PQM Analytical Laboratory Services

- Provide full capacity building laboratory services, including design, qualification, maintenance, calibration and metrology

- Provide hands-on technical training in quality control testing of medicines, to strengthen NQCL and local manufacturers towards ISO/IEC 17025 and/or WHO Prequalification

- Perform analytical tests for NQCLs who lack capacity, or for partners (UNICEF, USAID, WHO, NIH) prior to medicines procurement, clinical trials, etc.

- Support development of monographs for public health – Zinc Sulfate, Zinc Gluconate, Zinc Acetate, Vitamin-A liquid, CHX gel, MiniLab, etc

- Evaluate new field-based medicines detection tools, and train on existing tools such as MiniLab, CD-3, TruScan™
PQM Contributions to improving laboratory standard of practice in LMICs

(2009 – Present)

82 laboratories across 30 LMICs

20 Africa
  1 in MENA
  50 in Asia
  5 in CIS
  6 in LAC

20 Labs ISO accredited or WHO PQ’ed

4,022 laboratory personnel from 30 LMICs received training
(Laboratory QMS, Analytical testing, Instrument maintenance and calibration)
Good Manufacturing Practice (GMP) Services
Technical Assistance to Manufacturers

Provide hands-on training and consultation to manufacturers on pharmaceutical development and manufacturing

- Provide guidance on API process development and scale-up
- Provide guidance on drug product development and scale-up
- Troubleshoot API and formulation issues

Support for product dossier

- Assist with dossier compilation according to CTD format
- Guide critical research to fulfill dossier requirements

Support for facility GMP and BE/GCP compliance

- Manufacturing facility GMP compliance
- Contract research organization (CRO) GCPs and GLPs in support of bioequivalence studies

Continuous follow-up and support until product approval
High BE failures, high cost of BE studies, and surge in notices of concern make this a critical area for intervention.

PQM provides technical support to regulators and CROs in support of BA/BE studies according to GCPs and GLPs.

**Training of regulators, sponsors, CROs**
- BA/BE guidelines and requirement
- BE study protocol review
- CRO GCP support pertaining to study conduct, monitoring, termination, self-auditing, PK/Statistical analysis, reporting and documentation
- GLPs (ISO/IEC 15189, 17025)
PQM assists pharmaceutical manufacturers and regulator in low- and middle-income countries in achieving compliance with WHO PQ, as well as the regulatory requirements of stringent authorities such as the USFDA, EU/EDQM, TGA, etc.

Medicines regulatory authorities and manufacturers are trained in all aspect of dossier and cGMPs.

By obtaining the approval of WHO or a stringent regulatory authority, quality-assured priority medicines become available to the public health market.
Manufacturer Supported October 2009 to Present
(1971 Individuals - 55% female)

111 manufacturers, 22 countries
<table>
<thead>
<tr>
<th>No.</th>
<th>Product</th>
<th>Supplier</th>
<th>Certification</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Zinc Sulfate FPP</td>
<td>Lab Pharma Rodael</td>
<td>WHO PQ</td>
<td>2012</td>
</tr>
<tr>
<td>2</td>
<td>Cycloserine FPP</td>
<td>Dong-A Pharma</td>
<td>WHO PQ</td>
<td>2012</td>
</tr>
<tr>
<td>3</td>
<td>Streptomycin API</td>
<td>Shengxue Pharma</td>
<td>Spanish RA</td>
<td>2013</td>
</tr>
<tr>
<td>4</td>
<td>Isoniazid API</td>
<td>Second Pharma</td>
<td>WHO PQ</td>
<td>2013</td>
</tr>
<tr>
<td>5</td>
<td>Capreomycin API</td>
<td>NCPC Pharma</td>
<td>WHO PQ</td>
<td>2014</td>
</tr>
<tr>
<td>6</td>
<td>Capreomycin API</td>
<td>Hisun Pharma</td>
<td>WHO PQ</td>
<td>2014</td>
</tr>
<tr>
<td>7</td>
<td>Levofloxacin API</td>
<td>Langhua Pharma</td>
<td>WHO PQ</td>
<td>2014</td>
</tr>
<tr>
<td>8</td>
<td>Mebendazole API</td>
<td>Yabang Pharma</td>
<td>CEP</td>
<td>2014</td>
</tr>
<tr>
<td>9</td>
<td>Azithromycin FPP</td>
<td>HEC Pharma</td>
<td>WHO PQ</td>
<td>2014</td>
</tr>
<tr>
<td>10</td>
<td>BE CRO</td>
<td>PT Equilab</td>
<td>MHRA</td>
<td>2014</td>
</tr>
<tr>
<td>11</td>
<td>Capreomycin FPP</td>
<td>Hisun Pharma</td>
<td>WHO PQ</td>
<td>2015</td>
</tr>
<tr>
<td>12</td>
<td>Moxifloxacin API</td>
<td>Hisun Pharma</td>
<td>WHO PQ</td>
<td>2015</td>
</tr>
<tr>
<td>13</td>
<td>Kanamycin API (non-sterile)</td>
<td>Fuzhou Fuxin</td>
<td>USFDA</td>
<td>2015</td>
</tr>
<tr>
<td>14</td>
<td>Kanamycin API (non-sterile)</td>
<td>Fuzhou Fuxin</td>
<td>WHO PQ</td>
<td>2015</td>
</tr>
<tr>
<td>15</td>
<td>Zinc Sulfate FPP</td>
<td>Chi Pharma</td>
<td>UNICEF</td>
<td>2015</td>
</tr>
<tr>
<td>16</td>
<td>Moxifloxacin API</td>
<td>HEC Pharma</td>
<td>CEP</td>
<td>2015</td>
</tr>
<tr>
<td>17</td>
<td>Kanamycin FPP</td>
<td>Interpharma/SHP</td>
<td>Global Fund ERP</td>
<td>2015</td>
</tr>
<tr>
<td>18</td>
<td>Kanamycin API (Sterile)</td>
<td>Fuzhou Fuxin Pharm</td>
<td>WHO PQ</td>
<td>2016</td>
</tr>
<tr>
<td>19</td>
<td>Mebendazole API</td>
<td>Changzhou Yabang Pharma</td>
<td>WHO PQ</td>
<td>2016</td>
</tr>
<tr>
<td>20</td>
<td>Cycloserine API</td>
<td>Dong-A Pharma</td>
<td>WHO PQ</td>
<td>2016</td>
</tr>
<tr>
<td>21</td>
<td>Streptomycin API</td>
<td>NCPC Huasheng Pharma</td>
<td>WHO PQ</td>
<td>2016</td>
</tr>
<tr>
<td>22</td>
<td>Rifampicin API</td>
<td>Shenyang Antibiotic Manufacturer</td>
<td>WHO PQ</td>
<td>2016</td>
</tr>
<tr>
<td>23</td>
<td>Levofloxacin API</td>
<td>Shangyu Jingxin Pharma</td>
<td>WHO PQ</td>
<td>2016</td>
</tr>
<tr>
<td>24</td>
<td>Praziquantel API</td>
<td>Shanghai Jiayi Pharma</td>
<td>CEP</td>
<td>2016</td>
</tr>
<tr>
<td>25</td>
<td>Cycloeserine</td>
<td>Hisun Pharma</td>
<td>WHO PQ</td>
<td>2016</td>
</tr>
</tbody>
</table>
### Tuberculosis

**High Priority:**
- Kanamycin Sulfate API,
- Clofazimine API,
- Clofazimine 100mg capsules
- Linezolid API,
- Linezolid 600 mg coated (scored)
- Gatifloxacin API,
- Gatifloxacin 200mg Tablet
- Gatifloxacin 400mg Tablet
- Moxifloxacin API
- Rifapentine
- FDC (Rifapentine with INH)
- Pediatric first line fixed-dosed combination (preferably dispersible or crushable tablets):
  - Rifampicin(R) 75 mg/ Isoniazid 50mg / Pyrazinamide 150mg
  - Rifampicin(R) 75 mg/ Isoniazid 50mg

**Medium Priority**
- Capreomycin API
- Terizidone API
- Terizidone, tablet/capsule 250 mg
- Terizidone, tablet/capsule 300 mg
- Rifampicin API

---

### Neglected Tropical Disease

**High Priority:**
- Praziquantel API
- Praziquantel 600mg Tablet

**Medium Priority:**
- Albendazole API
- Albendazole 400mg tablet (chewable*, preferably scored)

**Low Priority:**
- Mebendazole API
- Mebendazole 500mg tablet (chewable*)

---

### Maternal, Newborn, Child Health

**High Priority:**
- Amoxicillin 250 mg scored DT
- 7.1% Chlorhexidine digluconate (4%) gel
- 7.1% Chlorhexidine digluconate (4%) sol

**Medium Priority:**
- Magnesium sulfate injection 500 mg/ml, in 2-ml and 10 ml ampoule
- Gentamicin injection 10mg/ml and 40 mg/ml, in 2-ml vial

**Medium - low Priority:**
- Oxytocin, injection 10 IU, 1-ml

**Low Priority:**
- Misoprostol 200-ug tablet
- Betamethasone injection 5.7 mg/ml (betamethasone sodium phosphate 3.9 mg/ml solution, or betamethasone acetate 3 mg aqueous suspension)
- Dexamethasone injection 4 mg injection (4 mg dexamethasone disodium phosphate in 1-ml ampoule)
PQM/USAID in organizing this workshop seeks to raise awareness about pharmaceutical quality and provide information to medicines regulatory agencies and manufacturers of TB and NTD medicines about opportunities for engaging PQM technical assistance.

PQM technical assistance to manufacturers and MRAs has helped to strengthen medicines quality-assurance systems globally, and contributed to ensuring that needed priority medicines are available to patients.

Wishing you a productive workshop and a wonderful time here in Thailand!
Thank You
Questions
USP–USAID Cooperative Agreements

- USP Drug Quality and Information Program (USP DQI) 2000–2005
- Promoting the Quality of Medicines (PQM) 2009–2014
- RPM Russia/NIS 1993–2000
- DQI Extended 2005–2010
- PQM Extended 2014–2019